CHPA Urges Nuanced, Risk-Based Approach To Nanotechnology
This article was originally published in The Tan Sheet
Executive Summary
FDA should not use size alone to regulate nanotechnology, the Consumer Healthcare Products Association says.
You may also be interested in...
FDA Draft Guidance Stretches Nanotech “Perhaps Massively” – Trade Group
FDA's draft guidance suggesting ingredients up to 1 micrometer in size that exhibit “altered properties” still qualify as nanomaterials should be revised to avoid confusion in the marketplace and promote international harmonization, according to the Personal Care Products Council.
FDA Draft Guidance Stretches Nanotech “Perhaps Massively” – Trade Group
FDA's draft guidance suggesting ingredients up to 1 micrometer in size that exhibit “altered properties” still qualify as nanomaterials should be revised to avoid confusion in the marketplace and promote international harmonization, according to the Personal Care Products Council.
FDA Draft Guidance Stretches Nanotech “Perhaps Massively” – Trade Group
FDA's draft guidance suggesting ingredients up to 1 micrometer in size that exhibit “altered properties” still qualify as nanomaterials should be revised to avoid confusion in the marketplace and promote international harmonization, according to the Personal Care Products Council.